Evidence map›Paper›PMID 42046772›Full record

ArticleNeuro-oncology advances

Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.

Collin T Le, Francesco Sanvito, Chuyin Yang, Blaine S C Eldred, Catalina Raymond, Terry J Prins, Addison Fisher, Tie Li, Linda M Liau, Robert A Chong and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Collin T LeDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.ORCID https://orcid.org/0000-0002-4762-3702
Francesco SanvitoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles.ORCID https://orcid.org/0000-0003-3379-9958
Chuyin YangDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Blaine S C EldredDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles.ORCID https://orcid.org/0000-0003-2757-439X
Terry J PrinsDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Addison FisherDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Tie Li
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, Los Angeles.
Robert A Chong
Phioanh Leia NghiemphuDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Albert LaiDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.ORCID https://orcid.org/0000-0002-7265-2986
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles.ORCID https://orcid.org/0000-0002-2764-6640

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0M
EPA EP-C-15-003NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA270027
6 · The paper itself

Abstract

Background: While bevacizumab, an anti-angiogenic monoclonal antibody, is approved for recurrent IDH wild-type glioblastoma, reports on clinical outcomes of IDH-mutant gliomas receiving this therapy are scarce. We retrospectively evaluated prognostic variables associated with outcomes in a cohort of recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab. Methods: Ninety-seven consecutive patients were retrospectively studied. Age, biological sex, Karnofsky performance status (KPS), number of prior recurrences, prior disease duration, 1p19q status, MGMT status, and therapy schemes were annotated as clinical variables. MRI datasets were used to quantify pre-bevacizumab contrast-enhancing tumor volume, immediate percent volumetric reduction after bevacizumab, and RANO radiographic response. Clinical and radiographic variables were evaluated as predictors of progression-free survival (PFS) and overall survival (OS) in multivariate Cox survival analyses. Results: Median PFS and OS were 3.62 and 10.49 months, respectively. A lower number of recurrences prior to bevacizumab initiation ( Conclusion: This is one of the first studies to report prognostic factors associated with clinical outcomes in IDH-mutant gliomas treated with bevacizumab. Early radiographic changes may be used to monitor treatment effectiveness, and bevacizumab significantly aids the tapering of corticosteroids in this patient subset.

Indexed as

bevacizumabcontrast-enhancementgliomaIDHRANO

Identifiers

PMID42046772
PMCPMC13110796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.